| REVIEW ARTICLE |
|
| Year : 2021 | Volume
: 8
| Issue : 1 | Page : 17-21 |
|
|
Update on promising biomarkers for multiple sclerosis
Faizan Ahmad1, Upasana Pathak2, Abhichandan Das2, Anusri Dhar3
1 Department of Medical Elementology and Toxicology, Jamia Hamdard University, Delhi, India
2 Centre for Biotechnology and Bioinformatics, Dibrugarh University, Assam, India
3 Department of Biotechnology, Pandu College, Guwahati, Assam, India
Correspondence Address:
Faizan Ahmad
Qno/B730, Hec Sector 2, Dhurwa, Ranchi, Jharkhand
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/jnbs.jnbs_40_20
|
|
|
Multiple sclerosis (MS) is a chronic autoimmune disease, in which there is chronic inflammation leading to neurodegeneration and demyelination. To detect MS at an early stage is impossible as it includes environmental factors and genetic factors as it varies from person to person. There are various methodologies that have been developed for the treatment of this disease; however, several complications as well as obstacles have been seen which are yet to be resolved. This review describes the biomarker for MS including microRNA and vaccine as a biomarker. Some of the drugs which are under phase II clinical trials are also discussed here. Testing and continuous validation is required for improvement where MS biomarkers are brought into clinical settings.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
